Analysts expect that Strongbridge Biopharma plc (NASDAQ:SBBP) will post sales of $2.98 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Strongbridge Biopharma’s earnings, with the lowest sales estimate coming in at $2.43 million and the highest estimate coming in at $3.29 million. The business is scheduled to report its next earnings report on Monday, March 26th.
On average, analysts expect that Strongbridge Biopharma will report full year sales of $2.98 million for the current year, with estimates ranging from $6.49 million to $7.35 million. For the next financial year, analysts forecast that the firm will post sales of $14.04 million per share, with estimates ranging from $9.39 million to $21.91 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Strongbridge Biopharma.
SBBP has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Oppenheimer initiated coverage on shares of Strongbridge Biopharma in a research report on Thursday, August 10th. They set an “outperform” rating and a $12.00 price objective for the company. ValuEngine lowered shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Strongbridge Biopharma in a report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $11.81.
Institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new stake in Strongbridge Biopharma during the 2nd quarter worth approximately $331,000. Citigroup Inc. acquired a new stake in Strongbridge Biopharma during the 2nd quarter worth approximately $338,000. Schwab Charles Investment Management Inc. acquired a new stake in Strongbridge Biopharma during the 2nd quarter worth approximately $332,000. Teachers Advisors LLC acquired a new stake in Strongbridge Biopharma during the 2nd quarter worth approximately $297,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in Strongbridge Biopharma during the 2nd quarter worth approximately $449,000. Institutional investors own 57.53% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Strongbridge Biopharma plc (SBBP) Will Announce Quarterly Sales of $2.98 Million” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/03/zacks-analysts-expect-strongbridge-biopharma-plc-sbbp-will-announce-quarterly-sales-of-2-98-million.html.
About Strongbridge Biopharma
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Strongbridge Biopharma plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Strongbridge Biopharma plc and related companies.